Researchers modify Alzheimer’s risk gene through targeted gene therapy
A new gene therapy approach converts the high-risk APOE gene variant linked to Alzheimer’s into a lower-risk form, offering potential prevention for carriers.
Written automatically from the sources below and not individually reviewed by a human editor.
Scientists at the University of Bristol have introduced a gene therapy method designed to alter the APOE gene variant, which is strongly associated with Alzheimer’s disease risk. The therapy aims to transform the high-risk APOE variant into a form that carries significantly lower risk. This development could provide a pathway to either prevent or delay the onset of Alzheimer’s in individuals who carry the APOE gene variant linked to higher susceptibility. The therapy is administered through the bloodstream, allowing it to reach the brain without invasive procedures. Early assessments indicate minimal unintended effects on other DNA regions, suggesting a favorable safety profile for potential clinical use. While further testing is required, this approach represents a promising step in addressing a major genetic risk factor for Alzheimer’s disease. The research was conducted at the Bristol Brain Centre and Southmead Hospital, highlighting a collaborative effort to advance therapeutic options for neurodegenerative conditions. The findings underscore the potential of gene editing to target specific biological pathways linked to disease development.
Sources
1 sourceThe article is grounded in the independently assessed evidence listed here.
Generated from retrieved source material, checked for evidence and provenance, and released through runtime safety controls.
Read our editorial standard →Spot a problem?
Reports go to the operator review queue and do not alter the article automatically.
